吉西他滨联合奈达铂治疗晚期复发鼻咽癌的临床观察  

The clinical efficacy of gemcitabine combined with nedaplatin for the treatment of advanced recurrent nasopharyngenal carcinoma

作　　者：夏俊贤[1] 陈敬华[1] 朱美琴[1] 申维玺[1] 

机构地区：[1]暨南大学第二临床医学院深圳市人民医院肿瘤内科,518020

出　　处：《北京医学》2013年第10期831-833,共3页Beijing Medical Journal

摘　　要：目的评价吉西他滨联合奈达铂治疗晚期复发鼻咽癌的临床疗效和不良反应。方法采用回顾性非随机方法收集晚期复发鼻咽癌患者46例,给予吉西他滨联合奈达铂化疗。吉西他滨1.0 g/m2,分别于第1天和第8天静脉点滴;奈达铂80 mg/m2,第1天静脉点滴。21 d为1个周期,所有病例均接受至少3个周期的化疗。结果 46例患者均完成计划化疗方案和随访。其中获完全缓解4例（8.7%）,部分缓解26例（56.5%）,稳定11例（23.9%）,进展5例（10.9%）,总有效率为65.2%。常见不良反应为骨髓毒性,Ⅲ~Ⅳ度中性粒细胞下降及血小板下降发生率分别为17.3%、15.2%,血红蛋白下降、恶心、呕吐、肝、肾损害均较轻。结论吉西他滨联合奈达铂方案治疗晚期复发鼻咽癌有较好的疗效,不良反应小,值得临床推广。Objective To study the efficacy of gemcitabine combined with nedaplatin（NDP） in the treatment of advanced recurrent nasopharyngeal carcinoma.Methods Forty-six cases of recurrent nasopharyngeal carcinoma were recruited and the following combined chemotherapy were given： gemcitabine,1.0g/m2intravenous drip,respectively,on the 1th day and 8th days of,and nedaplatin 80mg/m2,intravenous infusion on the 1th day.All cases had received at least 3 cycles of chemotherapy.Results Forty-six patients had completed chemotherapy and follow-up.CR was achieved in 4（8.7%）,PR in 26（56.5%）,SD in 11（23.9%）,PD in 5（10.9%）,and the total effective rate was 65.2%.The common side effects were bone marrow toxicity,with Ⅲ-Ⅳ annual decline of white blood cells and platelets respectively17.3%,15.2%,decline of hemoglobin,nausea,vomiting,slight liver and kidney function impairment.Conclusion Gemcitabine combined with nedaplatin in the treatment of advanced recurrent nasopharyngeal carcinoma have good curative effect,while this treatment regimen has few side effects so worthy for further clinical study.

关 键 词：吉西他滨 奈达铂 化学疗法 

分 类 号：R739.63[医药卫生—肿瘤]